Search Blogs
Tag Search Results For 'roche' (38)
The Best Way to Buy Into the Biotech Boom
Contrarian Profits | August 23rd 2008 by Contrarian Profits
There's a merger boom going on right now, but amid all the gloom, no one's really paying much attention. It could be because the sector in question has had a miserable few years itself, while almost every other industry was partying. But now, at last read more
A Safe, Easy to Use Chagas Treatment for Children
The Temas Blog | August 17th 2008
From the Drugs for Neglected Diseases Initiative (DNDi): Chagas Disease Partnership Will Deliver Safe, Easy-to-Use Treatment for Children An agreement between Drugs for Neglected Diseases initiative (DNDi) and the Pharmaceutical Laboratory of Pernam read more
Genentech Ditto’s ImClone, Rejects Offer
Stock Option Trading Blog: OptionsMentoring.com | August 13th 2008 by Options Mentoring
Genentech (DNA, $98.53, up $0.68) will not win an academy award for its efforts in “evaluating” take-over offers but give the company credit for at least trying. The “special committee” that has been evaluating the $44 billion bid fr read more
Genentech Hits All-Time High
Stock Option Trading Blog: OptionsMentoring.com | August 12th 2008 by Options Mentoring
Genentech (DNA, $98.12, up $0.29) has hit an all-time high this morning. Although we still haven’t heard from the company’s “special committee” that is evaluating the $44 billion bid from Roche, there’s a research note out this read more
GlaxoSmithKline (GSK) Boniva "Bone Loss" 300x250 (branded)
adverlicio.us | Online advertising archive | August 7th 2008
Roche tipped to be world's top drugmaker by 2014
Bio Saga | August 7th 2008 by Kamesh Janakiraman
Switzerland's Roche Holding AG is set to become the world's biggest drugmaker by sales in 2014, as current market leader Pfizer Inc skids down the rankings to sixth place, according to a study on Monday. The realignment of the global drugs industry r read more
Roche stops work on HIV drugs
James5 - eco, social and legal justice in Melbourne and abro… | August 3rd 2008 by Devon Whittle
It seems that Roche has stopped their research into HIV drugs. Though not directly linking it to the compulsory licensing/IP issues, one can’t help but wonder if it’s related. Elizabeth Pisani is right about the need for public funding/ow read more
Roche RA Drug Actemra Wins Support of US FDA Panel
Battling Arthritis | July 31st 2008 by arthritis_watcher
Roche is happy to announce that its rheumatoid arthritis drug Actemra (tocilizumab) has won the recommending approval of the US FDA’s Arthritis Advisory Committee. The committee’s vote was made after Roche presented results from five Phase II read more
No stealth molecule in CERA EPO: Roche denies WADA claim
Steroid Nation | July 24th 2008 by Gary G
Apparently WADA didn't understand the science, or WADA president John Fahey misspoke. Roche, the manufacturer of the new CERA variety of EPO. (Science Blogs) Roche Holding, which makes a version of a stamina-building drug illegally used by some athle read more
Switzerland’s Roche Makes $43.7 Billion Offer for U.S. Biotech…
Jutia Group | July 22nd 2008
Roche Holding Ltd. (OTC ADR: RHHBY) yesterday (Monday) announced a $43.7 billion offer for the 44% of Genentech Inc. (DNA) it doesn’t already own. Switzerland-based Roche’s $89 per share cash offer is almost a 9% premium over San Francisco-based read more
Roche Surprises Genentech With Takeover Bid
NewsVisual | July 22nd 2008 by NewsVisual
(NewsVisual, powered by IntellectSpace) -- Genentech Inc (NYSE: DNA) was in for a surprise when partner Roch Holdings AG made it's $44 billion takeover offer. The move could significantly change the way the two do business from here on out. read more
Roche Offers $44B For South San Francisco Giant Genentech
Square Feet Blog ...a Commercial Real Estate Blog | July 21st 2008 by J Alili
Roche (ADR: RHHBY) has offered $44B for Genentech (NYSE: DNA). The two companies both have a presence in the Bay Area, with Roche having offices in Palo Alto, and Genentech being headquartered in South San Francisco. Genentech currently occupies 48 read more
Roche To Stop Antiretroviral Research, Company Says
HIV and AIDS News Information DataBase | July 16th 2008 by James Edward Daugherty
Pharmaceutical company Roche in a memo circulated last week announced that it will stop research on antiretroviral drugs because of "disappointing results in clinical trials," the Financial Times reports. According to the memo, which was sent to HIV/ read more
'Return of the BIG BIRD-brained FLU-doo voodoo' or 'One Flu Over…
The Robert Scott Bell Show | July 15th 2008 by Robert Scott Bell
NATURALLY Speaking guest commentary by Christopher C. Barr: The summer movie season is in full swing and sequels are big again this year in films. Not to be left out of sequel mania is the unholy trinity of BIG government, BIG pharma and BIG media read more
Roche admits that it can’t cure HIV
Idiot Inc. | July 11th 2008 by Christy Kane
Roche, the Swiss pharmaceutical company has “suspended” its HIV research because none of its pending medicines is worth a damn. The research scientists that worked on this will be reassigned to other divisions. read more
One-Night Stands: Not the Love Brands Need
Branding Strategy Insider | July 8th 2008 by Derrick Daye
Consider, for a moment, how many people you have ever had sexual intercourse with. Now compare that figure with the number of people you have been in love with. Really in love. So in love that you could not live... read more
Your Personal Firewall Against an Acidic Body - Vinegar - Part 2
Natural Superfoods for Optimal Nutrition | July 5th 2008 by NaturalSuperfoods
The effects of vinegar are widely acknowledged. 3,500 years ago, a few winemakers made a mistake while making wine. The wine turned sour, resulting in the birth of vinegar. From that time onwards, vinegar has been used as a seasoning for food. // &# read more
Trastuzumab
HotMed.info | June 27th 2008 by Fouad Fakhreldeen
Trastuzumab (more commonly known under the trade name Herceptin) is a humanized monoclonal antibody that acts on the HER2/neu (erbB2) receptor. Trastuzumab’s principal use is as an anti-cancer therapy in breast cancer in patients whose tumors o read more
Back From the Pandemic Workshop
Disaster Preparedness Blog | June 26th 2008 by Keith Erwood
The Workshop was a huge success, very informative. Several people mentioned that it was one of the best events they have been to in quite some time. I will have to agree with that statement.I'll post some more on the event tomorrow. Since I was worki read more
Rituximab
HotMed.info | June 24th 2008 by Fouad Fakhreldeen
Rituximab, sold under the trade names Rituxan and MabThera, is a chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin’s lymphoma, B cell leukemia, and some autoimmune disorders. History Rituximab was developed by IDEC Pharma read more
The Trouble with Pfizer Is.. ( PFE, NVS, GSK, GENZ, RHHBY )
Rocks my Stocks | June 4th 2008 by brian
Pfizer’s revenues are currently stratospheric. In 2007 Pfizer brought in $48.3 billion in revenues, with $44.4 billion coming from pharmaceuticals sales. Of that $44.4 billion, $12.8 billion came from the sale of the best selling drug ever to hi read more
Mavi Bisiklet - Kanserde erken tanı için yola çık
Blog ve Wolkanca | June 2nd 2008 by Volkan YILMAZ
Kanserde hastalığında erken tanının önemine vurgu için ilk kez 2006 yılında T.C. Sağlık Bakanlığı Kanserle Savaş Daire Başkanlığı’nın desteği ve Türkiye Bisiklet Federasyonu’nun işbirlği ile yola çıkan Mavi Bisiklet read more
Roche’s Arthritis Drug Actemra™ Got Japanese Approval
Battling Arthritis | April 18th 2008 by arthritis_watcher
Roche Holding AG’s arthritis drug Actemra™ just won Japanese approval, which will then be sold by Roche’s Chugai unit. Actemra is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody. An extensive clinical de read more
Stripper to Symbolist: the Transcendental Science of Loie Fuller
ObjectifyThis | April 5th 2008 by Marina
Loie Fuller is not a famous name. Chances are, though, that you’ve heard of her contemporaries, like Isadora Duncan, who actually studied with Fuller in the beginning of her career. Yes, like Muriel Rukeyser, this is a female genius whose name read more
Pharma News 1_26
Impactiviti | January 26th 2008 by Steve Woodruff
Daiichi-Sankyo’s Welchol gets approval for improving glycemic control in adults with Type 2 diabetes. Novartis - for 11 years in a row - grabs the top spot in the Verispan Managed Care audit. Roche prevails in its takeover bid for Ventana. The read more
Roche engages in four additional AIDS Technology
Switzerland - Guide - News about Switzerland | January 10th 2008 by Gordian Hense
Transfers to strengthen local manufacturing in world’s poorest countries Free of charge expertise for factories in Bangladesh, Kenya, Tanzania and Zimbabwe Roche today announced that it has entered into four new technology transfers with local manu read more
Actions suisses: légers gains après un début faible
Bourse | December 28th 2007 by Rena
Zurich (AWP) - La Bourse suisse a viré dans le vert durant son dernier jour de négoce de l'année 2007, après un début dans le rouge. Le SMI devrait enregistrer cette année une perte de l'ordre de 2%. Après quatre années de hausse de cours, l' read more
Papa Aulin XVII da Roche [Flickr]
Vortexmind: Free your mind | December 20th 2007
Vortexmind posted a photo: Papa Aulin XVII da Roche, santo protettore del mal di capo. read more
¿Está Zeltia en los planes de futuro de Novartis?
bioinversor | December 8th 2007 by bioinversor
Hasta hace poco no era un candidato fuerte en las quinielas de la mayoría de los analistas. Gleevec (Glivec) ha funcionado bien y Novartis tiene un portfolio con 6 anticancerígenos, quizá por eso no se le ha tenido en cuenta hasta ahora. Esta sema read more
Bourse Suisse hausse générale
Bourse | December 6th 2007 by Rena
Zurich (AWP) - Après un début de séance en demi-teinte, la Bourse suisse s'est confortablement installée dans le vert à la mi-journée. Mais en l'absence de nouvelles importantes de sociétés, les volumes sont maigres, dans un marché calme. Ce read more
Subscribe To